OSR Holdings, Inc. (OSRH)
NASDAQ: OSRH · Real-Time Price · USD
1.250
-0.030 (-2.34%)
At close: May 9, 2025, 4:00 PM
1.260
+0.010 (0.80%)
After-hours: May 9, 2025, 6:38 PM EDT
Company Description
OSR Holdings, Inc. develops a portfolio of therapies and healthcare solutions in the United States, Europe, and South Korea.
The company develops immunotherapy products, including VXM01, VXM04, VXM06, VXM08, and VXM10 for cancer treatment; DRT102-sp for the treatment of lumbar stenosis, disc herniaton, and spinal; DRT102-dt for dental augmentation; DRT102-nu for nonunion bone fracture; and DRT101 for osteoarthritis.
It also provides medical devices. The company is based in Bellevue, Washington.
OSR Holdings, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Kuk Hwang |
Contact Details
Address: 10900 NE 4th Street, Suite 2300 Bellevue, Washington 98004 United States | |
| Phone | 425-635-7700 |
| Website | osr-holdings.com |
Stock Details
| Ticker Symbol | OSRH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840425 |
| ISIN Number | US68840D1028 |
Key Executives
| Name | Position |
|---|---|
| Kuk Hyoun Hwang | Chairman and Chief Executive Officer |
| Gihyoun Bang | Chief Financial Officer |
| Sang Hoon Kim | Head of Corporate Venture Capital |
| Dr. Constance Hofer | Chief Scientific Officer |
| Jun Chul Whang | Chief Legal Officer, Secretary and Director |